Auner, H W
Szydlo, R
Hoek, J
Goldschmidt, H
Stoppa, A M
Morgan, G J
Moreau, P
Attal, M
Marit, G
Russell, N
Brune, M
Cook, G
Sonneveld, P
Schönland, S
Garderet, L
Kröger, N
,
Article History
Received: 7 August 2014
Revised: 19 September 2014
Accepted: 23 September 2014
First Online: 10 November 2014
Competing interests
: HG has been a consultant for Janssen, Celgene, Novartis, Onyx and Millennium, has received honoraria from Janssen, Celgene, Novartis, Onyx, Chugai and Millennium, and has received research funding from Janssen, Celgene, Novartis and Chugai. GM has received remuneration from Janssen and Celgene. PM has been a consultant for and received honoraria from Celgene, Janssen, and Millenium. SS has received honoraria from Celgene and Janssen and research funding from Celgene. PS has received honoraria and research funding from Celgene, Janssen and Onyx. The remaining authors declare no conflict of interest.